FDA Approval Gives Dermatologists New Option for Uncontrolled AD

January 18, 2022

The FDA approved the topical JAK1/JAK2 inhibitor ruxolitinib for the treatment of mild to moderate atopic dermatitis in September 2021.

Expert Pearls for Treating Rosacea Patients
Diagnosing Skin Issues Pose Challenges in SOC
POLL: Are Your Patients Turning to CBD Products to Treat Skin Conditions?
Top Priorities for the AAD: 2022